Acute otitis media, sinusitis, pharyngitis, bronchitis
Renal Dose Adjustment
Hepatic Dose Adjustment
Caution: Use cautiously in
Pregnancy Category:C
Breastfeeding: Erythromycin: Excreted in breastmilk in small quantities and safely administered directly to infants, hence not expected to cause adverse events in the breastfed infant. Monitor the infant for irritability, diarrhea and candidiasis. As per one case report and unconfirmed epidemiologic evidence the risk of hypertrophic pyloric stenosis in infants might increase by maternal use of erythromycin during breastfeeding. Sulfisoxazole: In full term healthy infants, sulfisoxazole is considered acceptable for use, after the new born period. However alternative agents may be preferred in stressed, premature, jaundiced infants due to the risk of bilirubin displacement and kernicterus. This drug should be avoided while breastfeeding a G6PD-deficient infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 25 February 2011). According to manufacturer data a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother, because of the potential for the development of kernicterusin neonates due to the displacement of bilirubin from plasma proteins by sulfisoxazole.Erythromycin: This drug is compatible and considered safe with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 last accessed February 2011)
Erythromycin
Sulfisoxazole
US Trade Name(s)
US Availability
erythromycin/sulfisoxazole (generic)
Canadian Trade Name(s)
Canadian Availability
Pediazole
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability